CorMedix REZZAYO Phase III Data Bolsters Prophylaxis Market Opportunity

Event summary

  • CorMedix announced positive topline results from the Phase III ReSPECT trial for REZZAYO (rezafungin) in allogeneic hematopoietic stem cell transplantation (HSCT) patients.
  • The trial met its primary endpoint of non-inferiority versus a standard antimicrobial regimen (SAR) for fungal-free survival at Day 90 (60.7% vs. 59.0%).
  • REZZAYO demonstrated a favorable benefit/risk profile, including reduced toxicity-related discontinuations and drug-drug interactions.
  • CorMedix estimates a potential US market opportunity for REZZAYO in prophylaxis exceeding $2 billion.
  • The company plans to submit a supplemental New Drug Application (sNDA) to the FDA in 2H26.

The big picture

The HSCT patient population represents a significant unmet need for improved antifungal prophylaxis due to prolonged immunosuppression. REZZAYO’s non-inferiority to existing regimens, coupled with a potentially improved safety profile, positions it to capture a portion of the $2 billion US market. However, the success hinges on regulatory approval and successful commercialization against established competitors.

What we're watching

Regulatory Approval
The FDA’s response to the sNDA will be critical, and any requests for additional data could delay approval and impact CorMedix’s timeline.
Market Adoption
The success of REZZAYO will depend on physician adoption and payer reimbursement, which may be influenced by the perceived benefits over existing standard regimens.
Competition
The emergence of competing antifungal prophylaxis therapies could erode REZZAYO’s market share, particularly if those alternatives offer a more compelling value proposition.